NCT06226454View on ClinicalTrials.gov

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

PHASE1CompletedINTERVENTIONAL

Enrollment

39

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

June 12, 2024

Study Completion Date

June 12, 2024

Conditions

Pain

Interventions

DRUG

VX-993

Suspension for oral administration.

DRUG

Placebo

Suspension for oral administration.

Trial Locations (1)

84124

ICON Salt Lake City, Salt Lake City

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY